LG Chem will now proceed with Investigational New Drug (IND) enabling studies for Affimer PD-L1 antagonist programme LONDON & WETHERBY, England–(BUSINESS WIRE)–Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that LG Chem Life Sciences … [Read more…]
PARIS–(BUSINESS WIRE)–Ermium Therapeutics, a Paris-based biotech company developing innovative health products for auto-immune diseases, announced today the extension of its initial funding of €6.3 M to €12.3 M with Kurma Partners and Fountain Healthcare Partners. The company is discovering and developing small molecules, orally available, that are aimed at addressing a range of chronic auto-immune … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Biopharmaceuticals Contract Manufacturing Market Research Report by Product, Source, Contract Type, Service, Scale of Operation, Therapeutic Applications, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” report has been added to ResearchAndMarkets.com’s offering. The Global Biopharmaceuticals Contract Manufacturing Market size was estimated at USD 27.99 billion in 2021 and expected to … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Neonatal Ventilators Market – Growth, Trends, COVID-19 Impact, and Forecasts (2022 – 2027)” report has been added to ResearchAndMarkets.com’s offering. The global neonatal ventilators market studied was anticipated to grow with a CAGR of nearly 6.8% during the forecast period. Companies Mentioned Air Liquide Medical Systems India Breas Medical Drgerwerk AG & Co. … [Read more…]
PD-1 inhibitor tislelizumab plus chemotherapy demonstrated a statistically significant and clinically meaningful survival benefit, extending survival by more than six months compared to chemotherapy alone Incidence of most common treatment-related adverse events similar for both arms of the study, with no new safety signal identified for tislelizumab CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING–(BUSINESS WIRE)–$BGNE … [Read more…]
LONDON & SINGAPORE–(BUSINESS WIRE)–#AI—MultiOmic Health, an artificial intelligence (AI)-enabled drug discovery company, and Mesh Bio, a digital health startup transforming chronic disease management through predictive analytics, today announce their partnership to conduct an observational clinical study on patients with chronic metabolic disease and increased risk of complications such as chronic kidney disease. The partnership will … [Read more…]
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses NEW YORK & MAINZ, Germany–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. … [Read more…]
MORRISVILLE, N.C.–(BUSINESS WIRE)–#geneediting–Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and … [Read more…]
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter of Fiscal 2022 on Wednesday, August 3, 2022, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on … [Read more…]
IRVING, Texas–(BUSINESS WIRE)–McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2023 financial results after market close on Wednesday, August 3, 2022. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson’s … [Read more…]
